KR20060066729A - 우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합 - Google Patents

우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합 Download PDF

Info

Publication number
KR20060066729A
KR20060066729A KR1020067003210A KR20067003210A KR20060066729A KR 20060066729 A KR20060066729 A KR 20060066729A KR 1020067003210 A KR1020067003210 A KR 1020067003210A KR 20067003210 A KR20067003210 A KR 20067003210A KR 20060066729 A KR20060066729 A KR 20060066729A
Authority
KR
South Korea
Prior art keywords
phenyl
propyl
methyl
chloro
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020067003210A
Other languages
English (en)
Korean (ko)
Inventor
미카엘 디드릭센
윌리거스 산드라 호그
외른 아른트
Original Assignee
하. 룬트벡 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하. 룬트벡 아크티에 셀스카브 filed Critical 하. 룬트벡 아크티에 셀스카브
Publication of KR20060066729A publication Critical patent/KR20060066729A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020067003210A 2003-08-21 2004-08-18 우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합 Withdrawn KR20060066729A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49673803P 2003-08-21 2003-08-21
DKPA200301198 2003-08-21
DKPA200301198 2003-08-21

Publications (1)

Publication Number Publication Date
KR20060066729A true KR20060066729A (ko) 2006-06-16

Family

ID=34219531

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067003210A Withdrawn KR20060066729A (ko) 2003-08-21 2004-08-18 우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합

Country Status (12)

Country Link
US (1) US20060223857A1 (cg-RX-API-DMAC7.html)
EP (1) EP1660130A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007502785A (cg-RX-API-DMAC7.html)
KR (1) KR20060066729A (cg-RX-API-DMAC7.html)
CN (1) CN1867358A (cg-RX-API-DMAC7.html)
AU (1) AU2004266057A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0413587A (cg-RX-API-DMAC7.html)
CA (1) CA2536275A1 (cg-RX-API-DMAC7.html)
IS (1) IS8277A (cg-RX-API-DMAC7.html)
MX (1) MXPA06002002A (cg-RX-API-DMAC7.html)
NO (1) NO20061167L (cg-RX-API-DMAC7.html)
WO (1) WO2005018676A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458689B1 (en) * 2001-12-20 2007-04-11 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
US8604080B2 (en) * 2007-02-14 2013-12-10 W. Louis Cleveland High dose glycine as a treatment for obsessive-compulsive disorder and obsessive compulsive spectrum disorders
CN101338337B (zh) * 2007-07-04 2011-11-02 北京华安佛医药研究中心有限公司 多态性位点基因型预测抑郁症及药效的用途、方法和试剂盒
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
CN102949364A (zh) * 2011-08-30 2013-03-06 天津药物研究院 一种含有效成分盐酸维拉佐酮的缓释片
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
AU730789B2 (en) * 1996-05-31 2001-03-15 Nps Pharmaceuticals, Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
DOP2001000189A (es) * 2000-06-30 2002-03-30 Pfizer Prod Inc Benzofenonas y sulfonas como inhibidores de la captación de glicina
HUP0302778A3 (en) * 2000-07-21 2005-02-28 Lundbeck & Co As H Novel compounds and their use as glycine transport inhibitors
EP1458689B1 (en) * 2001-12-20 2007-04-11 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
AU2003240434A1 (en) * 2002-06-20 2004-01-06 H. Lundbeck A/S Combination therapy wherein a serotinin reuptake inhibitor is used
UA80055C2 (en) * 2003-05-27 2007-08-10 Forest Laboratories Combination of nmda-receptor antagonist and selective inhibitor of serotonin reuptake for a depression and other pscihiatric disorders treatment

Also Published As

Publication number Publication date
JP2007502785A (ja) 2007-02-15
US20060223857A1 (en) 2006-10-05
EP1660130A1 (en) 2006-05-31
IS8277A (is) 2006-01-31
MXPA06002002A (es) 2006-05-17
CN1867358A (zh) 2006-11-22
AU2004266057A1 (en) 2005-03-03
WO2005018676A1 (en) 2005-03-03
NO20061167L (no) 2006-03-13
BRPI0413587A (pt) 2006-10-17
CA2536275A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
US20130217776A1 (en) Combination of a Serotonin Reuptake Inhibitor and Agomelatine
EP1545552B1 (en) Combination therapy wherein a serotonin reuptake inhibitor is used
JP2007502785A (ja) うつ病の治療のためのセロトニン再取り込み阻害剤およびグリシントランスポーター1型阻害剤の併用
KR20060124639A (ko) 세로토닌 재흡수 억제제 및 히스타민 3 수용체안타고니스트, 역 아고니스트 또는 부분 아고니스트의 조합
JP2007513896A (ja) セロトニン再取り込み阻害剤およびヒスタミン3受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用
JP2007513896A6 (ja) セロトニン再取り込み阻害剤およびヒスタミン3受容体アンタゴニスト、インバースアゴニストまたはパーシャルアゴニストの併用
JP2007504181A (ja) セロトニン再取り込み阻害剤およびロキサピンの併用
KR20060072127A (ko) 세로토닌 재흡수 억제제 및 록사핀의 조합
US20080167290A1 (en) Combination of a Serotonin Reuptake Inhibitor and Amoxapine
KR20060072126A (ko) 세로토닌 재흡수 억제제 및 아목사핀의 조합
ZA200601084B (en) The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
MXPA06005127A (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
CA2579520A1 (en) Combination therapy wherein a serotonin reuptake inhibitor is used
ZA200409278B (en) Combination therapy wherein a serotonin reuptake inhibitor is used

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid